Docusign Envelope ID: CFC024E3-4322-47E5-943B-CC66D67780E6

California Transparency in Supply Chains Act and United Kingdom Modern Slavery Act

2025 Modern Slavery and Human Trafficking Statement

LivaNova PLC ("LivaNova" or the "Company") supports the goals of the California Transparency in Supply Chains Act of 2010 and the United Kingdom Modern Slavery Act of 2015 and is committed to eradicating modern slavery and human trafficking from its business activities and supply chain. This statement sets out LivaNova's efforts towards this commitment for the fiscal year starting 1 January 2025 and ending 31 December 2025.

BUSINESS OVERVIEW

LivaNova is a market-leading global medical technology company that designs, develops, manufactures, markets, and sells products, therapies, and services that are consistent with LivaNova's mission to "create ingenious medical solutions that ignite patient turnarounds." Headquartered in London, England, LivaNova is comprised of two reportable segments: Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories. The Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and difficult-to-treat-depression. The Neuromodulation segment also includes the development and clinical testing of devices for treating obstructive sleep apnoea.

As of 31 December 2025, LivaNova had approximately 3,300 employees worldwide, representing more than 80 nationalities and located in 34 countries.

POLICIES AND INTERNAL ACCOUNTABILITY

Mission
LivaNova's mission is to "create ingenious medical solutions that ignite patient turnarounds." LivaNova can only uphold this mission with the trust and respect of its stakeholders, including patients, healthcare professionals, employees, suppliers, the communities in which the Company operates, and shareholders. That trust and respect comes with LivaNova meeting the highest standards of business ethics and compliance. It is not only what LivaNova does but how the Company does it, and this includes taking steps to ensure that LivaNova complies, in all aspects, with laws related to modern slavery and human trafficking.

Code of Ethics and Business Conduct
LivaNova's Code of Ethics and Business Conduct (the "Code") applies to all LivaNova employees and Officers, the Company's Board of Directors, and individuals and companies acting on LivaNova's behalf. The Code provides a framework of principles, guidelines, and policies that are aligned with ethical, social, and environmental responsibilities. Any form of slavery, including unfair wages, debt bondage, child labour, or forced labour in the Company's operations or in the operations throughout the Company's supply chain, is not tolerated. A copy of the Code is available on LivaNova's website, along with clear communication channels for reporting violations or concerns in good faith. The Code provides that violation of any laws, Company policies, procedures, or other written guidance, and any manager who knowingly permits or directs a subordinate to do so, may be disciplined accordingly, up to and including termination of employment.

Third-Party Code of Conduct
LivaNova's Third Party Code of Conduct is oriented towards its third-party consultants, suppliers, and other business partners and was refreshed in early 2025, to strengthen human rights and labour protections, including relating to non-discrimination, child and young labour, fair working conditions, freedom of movement, ethical recruitment practices, and mechanisms for workers to raise concerns without fear of retaliation. It defines the standards LivaNova expects of its third parties when doing business with the

Docusign Envelope ID: CFC024E3-4322-47E5-943B-CC66D67780E6

Company, in addition to all applicable laws, regulations, and industry standards. In addition, it includes an expectation for third parties to pass on these standards to their subsidiaries, subcontractors, and affiliates, and have in place processes to monitor their compliance. LivaNova does not tolerate any form of slavery or forced labour in the operations of its third parties. The Third Party Code of Conduct is published externally as well as within LivaNova's purchase order terms and conditions. If LivaNova were to determine that a third-party was not aligned with the Company's Third-Party Code of Conduct, LivaNova reserves the right to take corrective measures, which may include immediate termination of the business relationship.

RISKS/AUDIT/DUE DILIGENCE

Risks

LivaNova has manufacturing and research facilities located in the U.S., Italy, Germany, Australia, and Brazil. For LivaNova employees, a number of background checks are conducted during the recruitment and onboarding process including identification verification and confirmation of right to work, which collectively help minimise the risk of forced or child labour. In addition, LivaNova requires third-party partners, including agencies that provide on-site contract workers, to meet the Company's standards.

As a medical device company, LivaNova is required to comply with regulations requiring formal programmes for selecting, qualifying, and auditing certain third parties with which LivaNova does business. These programmes are managed by LivaNova throughout its sourcing and procurement processes, at times with third-party audit assistance.

Due Diligence

LivaNova evaluates relevant risks within its supply chain through automated screening activities. These screenings are conducted weekly for suppliers and customers, and consider sanction lists such as the Kharon Forced Labour and the Descartes Anti-Bribery and Anti-Corruption datasets, which include companies and supply chains targeted by the Uyghur Forced Labor Prevention Act (UFLPA), raw materials manufactured in whole or in part in Xinjiang, China (a region declared by the U.S. State Department, European Parliament, and Canadian Parliament to be committing genocide against ethnic and religious minorities), and companies co-located with entities flagged as high risk for forced labour. LivaNova's compliance procedures and due diligence activities also include enhanced screening and review of high-risk indirect third parties, including transactions with sanctioned countries. LivaNova reserves the right to take any necessary mitigation action to address any potential risk of modern slavery and human trafficking within the Company's business operations and third-party partners. The risk that modern slavery or human trafficking exists within the Company's Tier 1 supply chains was assessed to be low for LivaNova's cardiopulmonary products and the commercially distributed neuromodulation therapies. To date, LivaNova has not identified any evidence of modern slavery or human trafficking in its direct supplier base. The Company does not require direct suppliers to certify compliance with anti-slavery and human trafficking laws in the country or countries in which they do business. LivaNova continues to assess the Company's approach and practices to strengthen accountability and transparency across its supply chain.

Audit

LivaNova reserves the right to verify and evaluate supplier compliance with the human rights principles of its Third Party Code of Conduct by way of an assessment and/or an audit, including onsite auditing of direct suppliers. Audits may be announced in advance, are performed by LivaNova or independent third parties contracted by LivaNova and may include site visits. LivaNova conducts audits based on the need determined from a supply risk perspective, informed by LivaNova's risk assessment procedures. In 2025, several supplier audits were carried out across various locations, including in the U.S., Italy, Germany, Australia, Brazil, Dominican Republic, India, Mexico, and Uruguay.

TRAINING, ACCOUNTABILITY, AND EFFECTIVENESS

LivaNova's annual compliance training program consists of core training on the Company's Code for all employees. This training encompasses modern slavery, human trafficking, and other human rights topics and is regularly refreshed and made available to employees worldwide to ensure a deep understanding of

Docusign Envelope ID: CFC024E3-4322-47E5-943B-CC66D67780E6

compliance obligations, product regulations, and the ethical standards the Company upholds. While the Code training does not explicitly cover mitigation of risks within the supply chains of products, LivaNova's employees have been trained to use the Company's systems and procedures that have been developed to mitigate such risks. At LivaNova, open and transparent communication is a core pillar of the compliance culture. Employees and third parties are encouraged to raise questions or concerns in good faith directly to LivaNova leadership, Compliance, Human Resources, or Legal. Additionally, employees and third-parties may contact the LivaNova Ethics Helpline, a hotline which is available globally, 24/7 and in many languages, to report concerns about potential violations of the Company's Code, LivaNova's Third-Party Code of Conduct, policies and procedures, or applicable laws and regulations. This is supported by LivaNova's Global Speak Up and Non-Retaliation Policy. Senior leadership communicates the Company's unwavering commitment to ethical conduct regularly, reinforcing the importance of compliance at every level of the organisation. LivaNova has established a programme to address modern slavery and human trafficking and identify potential risks in its operations and supply chain, supported by screening activities, supplier audits and assessments, Code training, and the LivaNova Ethics Helpline. The Company also monitors evolving industry practices through external partners and peer monitoring which may inform enhancements to policies, procedures, and risk mitigation actions where relevant.

In 2025, the above monitoring activities did not identify any confirmed instances of modern slavery or human trafficking within LivaNova's operations or direct supplier base, and the Company has not received any complaints via the LivaNova Ethics Helpline in relation to modern slavery and human trafficking.

LOOKING AHEAD

LivaNova is committed to identifying areas for improvement in its approach to preventing modern slavery and human trafficking and will continue to engage with stakeholders and monitor internationally recognised standards, applicable laws, and regulatory changes throughout its global business operations to inform future updates to related practices and policies.

/s/ Vladimir Makatsaria
Chief Executive Officer LivaNova PLC
[DATE TO BE INSERTED] April 2026

Date: Approved 22 April 2026 by the LivaNova Board of Directors

2026-04-24 | 20:04 BST

Signed by:

264F5AE8783D48E...